<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJBM</journal-id><journal-title-group><journal-title>Hans Journal of Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2161-8976</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJBM.2021.112010</article-id><article-id pub-id-type="publisher-id">HJBM-41663</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJBM20210200000_57695834.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  经鼻腔给药的纳米颗粒及其治疗脑部疾病的进展
  Nanoparticles Administered through Nasal Cavity and Its Progress in the Treatment of Brain Diseases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邓</surname><given-names>爱林</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>柯</surname><given-names>腾飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>玥媛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>廖</surname><given-names>承德</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>云南省肿瘤医院/昆明医科大学第三附属医院放射科，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>69</fpage><lpage>74</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  血脑屏障是人脑的一种重要功能性屏障，也是药物治疗脑部疾效果欠佳的重要原因。鼻腔给药作为一种非侵入性的脑部给药方式，联合纳米颗粒能有效透过血脑屏障，提高进入脑内的药物浓度，从而改善脑部疾病的治疗效果。本文章将对适用于经鼻腔给药的纳米颗粒，用于治疗脑部疾病的研究进展进行综述。
   Blood-brain barrier is an important functional barrier of human brain, and it is also an important reason for the poor effect of drug treatment on brain diseases. Nasal administration, as a non-invasive way of brain administration, combined with nanoparticles, can effectively penetrate the blood-brain barrier and increase the concentration of drugs entering the brain, thus improving the therapeutic effect of brain diseases. In this article, we will review the research progress of na-noparticles for intranasal administration in the treatment of brain diseases.
 
</p></abstract><kwd-group><kwd>鼻腔给药，脑部疾病，脂质纳米颗粒，纳米乳液，壳聚糖纳米颗粒, Nasal Administration</kwd><kwd> Brain Diseases</kwd><kwd> Lipid Nanoparticles</kwd><kwd> Nanoemulsion</kwd><kwd> Chitosan Nanoparticles</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>血脑屏障是人脑的一种重要功能性屏障，也是药物治疗脑部疾效果欠佳的重要原因。鼻腔给药作为一种非侵入性的脑部给药方式，联合纳米颗粒能有效透过血脑屏障，提高进入脑内的药物浓度，从而改善脑部疾病的治疗效果。本文章将对适用于经鼻腔给药的纳米颗粒，用于治疗脑部疾病的研究进展进行综述。</p></sec><sec id="s2"><title>关键词</title><p>鼻腔给药，脑部疾病，脂质纳米颗粒，纳米乳液，壳聚糖纳米颗粒</p></sec><sec id="s3"><title>Nanoparticles Administered through Nasal Cavity and Its Progress in the Treatment of Brain Diseases<sup> </sup></title><p>Ailin Deng<sup>*</sup>, Tengfei Ke, Yueyuan Luo, Shasha Bao, Chengde Liao<sup>#</sup></p><p>Department of Radiology, Yunnan Cancer Hospital/Third Affiliated Hospital of Kunming Medical University, Kunming Yunnan</p><p><img src="//html.hanspub.org/file/6-1530164x4_hanspub.png" /></p><p>Received: Mar. 10<sup>th</sup>, 2021; accepted: Mar. 24<sup>th</sup>, 2021; published: Apr. 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/6-1530164x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Blood-brain barrier is an important functional barrier of human brain, and it is also an important reason for the poor effect of drug treatment on brain diseases. Nasal administration, as a non-invasive way of brain administration, combined with nanoparticles, can effectively penetrate the blood-brain barrier and increase the concentration of drugs entering the brain, thus improving the therapeutic effect of brain diseases. In this article, we will review the research progress of nanoparticles for intranasal administration in the treatment of brain diseases.</p><p>Keywords:Nasal Administration, Brain Diseases, Lipid Nanoparticles, Nanoemulsion, Chitosan Nanoparticles</p><disp-formula id="hanspub.41663-formula21"><graphic xlink:href="//html.hanspub.org/file/6-1530164x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1530164x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-1530164x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>受血脑屏障的限制，进入脑内的药物往往浓度较低，这是多数药物治疗脑部疾病效果欠佳的原因，所以克服血脑屏障、提高进入脑内的药物浓度成为目前研究的热点。一些侵入性经颅给药和短暂开放血脑屏障的给药方法，虽然可以提高脑内药物浓度，但成功率低且部分属于有创方式。相比之下，鼻腔给药可以通过嗅觉上皮和嗅神经通路绕过血脑屏障将药物运送至大脑，具有非侵入性、易于给药、避免肝脏的首过代谢等优点，有望成为一种可靠且有前途的脑部给药方式。近年来，纳米颗粒被证实可以穿过血脑屏障，具有其粒径小、易于装载药物、可以添加表面黏附剂增强脑靶向性等优势。将纳米颗粒与鼻腔给药联合，有望提高进入脑内的药物浓度，并改善对脑部疾病的治疗效果。</p><p>本文将对用于鼻腔给药的纳米颗粒，例如：脂质纳米颗粒(Lipid nanoparticles, LNs)、纳米乳液(Nanoemulsions, NEs)、壳聚糖纳米颗粒等，及其用于治疗脑部疾病的研究进展进行综述。</p></sec><sec id="s6"><title>2. 利用鼻腔给药治疗脑部疾病的机制</title><p>经鼻腔给药后，药物首先暴露于鼻黏膜，鼻黏膜上存在嗅觉上皮，而嗅觉上皮又由嗅神经和三叉神经支配，因此，鼻内给药的主要途径是通过嗅神经和三叉神经通路进入绣球 [<xref ref-type="bibr" rid="hanspub.41663-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41663-ref2">2</xref>]，然后进入脑组织或脑脊液。其中，经嗅觉途径发生的转运常被分为缓慢的神经元内(轴突内)转运和较快的神经元外(神经细胞外间隙)转运 [<xref ref-type="bibr" rid="hanspub.41663-ref3">3</xref>]；入脑后，药物主要通过简单扩散方式进入大脑的其他区域，动脉脉动作用也会参与其中 [<xref ref-type="bibr" rid="hanspub.41663-ref4">4</xref>]。</p><p>目前临床可用的脑内给药途径，主要包括：脑室内或脑实质内注射、使用微型泵的颅内递送、导管输注、聚焦超声开放血脑屏障等，但他们常依赖一定的侵入性操作并具有风险 [<xref ref-type="bibr" rid="hanspub.41663-ref5">5</xref>]。相比之下，鼻腔给药部位易于接近、可以避免肝对药物的首过代谢，经鼻腔给药的药量通常比口服剂量低2~10倍 [<xref ref-type="bibr" rid="hanspub.41663-ref6">6</xref>]。近些年，利用鼻腔给药，向中枢神经系统输送多种治疗药物(包括小分子和大分子、肽和蛋白质、合成基因等)，用于治疗阿尔茨海病在内的多种退行性神经疾病 [<xref ref-type="bibr" rid="hanspub.41663-ref7">7</xref>]。</p></sec><sec id="s7"><title>3. 经鼻腔输送的纳米颗粒及其临床应用</title><p>纳米颗粒往往指直径10~100 nm之间的天然或人造聚合物，目前已证明这些物质可有效地穿越血–脑屏障或血–脑脊液屏障，能有效地将搭载的治疗药物输送至脑内靶点 [<xref ref-type="bibr" rid="hanspub.41663-ref8">8</xref>]。尤其小直径的颗粒可以通过(口服和鼻内)粘膜给药，并穿透毛细血管或粘膜表面最后进入脑内 [<xref ref-type="bibr" rid="hanspub.41663-ref9">9</xref>]。</p><p>纳米颗粒作为载体，除具有靶向性好和表面积/体积比较高等优势外，还能提高装载药物的生物利用度和药物靶向性。多数情况下，它能够保护被装载的药物免受生物/化学降解、P-gp流出蛋白的细胞外转运作用 [<xref ref-type="bibr" rid="hanspub.41663-ref1">1</xref>]。经过粘附聚合物和吸收促进剂表面修饰后，纳米颗粒能延长药物与鼻粘膜的接触时间，增强药物的渗透性。相比其他类型的制剂，纳米颗粒还能够进行持续、可控地药物释放，相应减少患者所需的给药剂量和给药频率。</p><sec id="s7_1"><title>3.1. 脂质纳米颗粒(LNs)</title><p>因为脂质基质具有良好的生物相容性，脂质纳米颗粒被广泛应用于亲脂性药物输送 [<xref ref-type="bibr" rid="hanspub.41663-ref10">10</xref>]。LNs由多种脂质以及表面活性剂/辅助表面活性剂制成，是一种安全、通用的给药载体，适用于经鼻腔等多种给药途径。主要包括固体脂质纳米粒(Solid lipid nanoparticles, SLNs)、纳米结构脂质载体(Nanostructured lipid carrier, NLC)、脂质–药物缀合物(Lipid-drug conjugate, LDC)和脂质纳米胶囊(Lipid nanocapsules, LNCs)，其次是囊泡、转移体和脂质体。与聚合物或无机纳米颗粒相比，这些脂质纳米颗粒生物相容性更强，且便于大规模生产。除此之外，脂质纳米粒对蒸汽灭菌是稳定的，即使存在不饱和脂质过氧化的风险，也可以使用γ-辐射灭菌 [<xref ref-type="bibr" rid="hanspub.41663-ref10">10</xref>]。由于在环境温度和体温下的低熔点和固体度等优点 [<xref ref-type="bibr" rid="hanspub.41663-ref11">11</xref>]，目前对于鼻腔给药的研究主要集中于SLN。</p><p>SLN装载药物后，可用于治疗阿尔兹海默病、亨廷顿病等神经疾病。装载到SLN后，乙酰胆碱酯酶抑制剂(利伐斯的明)显示出更高的药物扩散效率，可用于治疗阿尔兹海默病。在利用绵羊鼻粘膜的离体研究中，SLN作为药物载体未导致鼻纤毛损伤或细胞坏死，表明其用于鼻腔给药是安全的 [<xref ref-type="bibr" rid="hanspub.41663-ref12">12</xref>]。塔伦氟比尔是一种非甾体抗炎药，在治疗阿尔茨海默病方面表现出一定潜力。经SLN搭载和鼻腔给药后，塔伦氟比尔在大鼠中获得了满意的脑内生物分布，优于静脉和口服给药途径 [<xref ref-type="bibr" rid="hanspub.41663-ref13">13</xref>]。在动物亨廷顿病模型中，携带迷迭香酸的SLN，无创性从鼻到脑给药，结果证实这是一种有效且有前途的治疗亨廷顿病的方法 [<xref ref-type="bibr" rid="hanspub.41663-ref14">14</xref>]。此外，抗精神病、抗抑郁、镇静和抗癫痫药物也是LN介导的鼻–脑给药的合适候选者。另外，一种非典型的抗精神病药物——利培酮，由SLN负载后经鼻腔给药，药效学和药代动力学结果表明载有利培酮的固体脂质纳米颗粒在脑靶向方面优于单纯的利培酮 [<xref ref-type="bibr" rid="hanspub.41663-ref15">15</xref>]。</p><p>经鼻脑给药的脂质纳米颗粒在治疗脑部疾病中虽有很多优势，但也存在一些不足。脂质纳米颗粒普遍存在药物负载能力较低的问题，SLNs装载的药物量有限且在储存期间会少量排出，与之相比，NLCs能增加药物的装载量。其次，有研究发现在载药量较低时，NLCs释放药物比SLNs更快，并且NLCs在25℃时显示出比SLNs更好的稳定性；但在高载药量时，两种制剂都能持续、长期的释放药物，二者没有显著差异 [<xref ref-type="bibr" rid="hanspub.41663-ref16">16</xref>]。除此之外，用于鼻腔给药的脂质纳米颗粒研究，多数在动物实验中进行，只有很少的几个完成了临床试验，在商业上并太不成功。</p></sec><sec id="s7_2"><title>3.2. 纳米乳液(NEs)</title><p>又称微乳液，是使用适当的表面活性剂、稳定的水包油(O/W)或油包水(W/O)分散体 [<xref ref-type="bibr" rid="hanspub.41663-ref17">17</xref>]，可以通过口服以及鼻腔等不同途径给药 [<xref ref-type="bibr" rid="hanspub.41663-ref18">18</xref>]。制备NEs需要的表面活性剂通常比其他胶体分散体少，需要乳化剂来促进NE的形成并确保其在储存期间的稳定性，乳化剂也可以是蛋白质和脂类。NEs平均液滴直径约为100 nm，但也有文献中报道了高达300 nm的NEs [<xref ref-type="bibr" rid="hanspub.41663-ref6">6</xref>]。因为NEs是小尺寸的液滴，所以它的特征在于比其他制剂具有更高的表面积/体积比，并且具有长期的物理稳定性、小液滴尺寸和最佳溶解性能等优势，因此可以解决药物溶解度和药物稳定性的问题 [<xref ref-type="bibr" rid="hanspub.41663-ref17">17</xref>]。</p><p>纳米乳已被用于鼻腔给药和治疗大多数脑部疾病，它可提高药物利用度和减少药物剂量，从而减小一些药物的不良反应。有研究者在小鼠癫痫模型中，对比托吡酯纳米乳剂的鼻腔给药和口服给药效果，结果经鼻腔给药组的脑内药物浓度明显高于经口服给药组 [<xref ref-type="bibr" rid="hanspub.41663-ref19">19</xref>]。对于阿尔兹海默病，有研究者用Tc99m标记的NEs进行大鼠体内实验，观察到装载了盐酸多奈哌齐的NEs经鼻腔给药后脑内药物浓度明显升高，有望成为治疗阿尔茨海默病的一种新方法 [<xref ref-type="bibr" rid="hanspub.41663-ref20">20</xref>]。有研究者经猪鼻腔给予丁苯那嗪纳米乳剂，结果表明这是一种治疗与亨廷顿氏病相关运动亢进的可行替代方案 [<xref ref-type="bibr" rid="hanspub.41663-ref21">21</xref>]。</p><p>NEs具有尺寸小、可制成不同剂型、稳定性高、溶解度好、各种途径均可给药(包括鼻腔给药)等优势，但NEs中所使用的脂质数量取决于乳剂的种类和系统中装载药物的溶解度 [<xref ref-type="bibr" rid="hanspub.41663-ref22">22</xref>]，且油相时必须能溶解和维持药物浓度，所以乳剂的增溶能力至关重要。此外，还需要尽可能高的药物溶解度来减少制备NEs时所需的脂质，同时减少表面活性剂用量以减小毒性。尽管在体外和体外都有令人鼓舞的结果，但似乎因为缺乏确定制剂对鼻粘膜和纤毛的影响的详细的毒理学研究以及缺乏广泛的临床试验，而导致纳米乳剂在人鼻中的应用受到阻碍 [<xref ref-type="bibr" rid="hanspub.41663-ref17">17</xref>]。</p></sec><sec id="s7_3"><title>3.3. 壳聚糖纳米颗粒</title><p>壳聚糖(Chitosan, CS)是唯一一种具有良好生物相容性、生物降解性和安全性的天然碱性多糖，也是鼻腔给药中良好的吸收促进剂。由于壳聚糖纳米颗粒表面带正电荷，而细胞膜表面带负电荷，从而增加了在鼻粘膜上的停留时间，有利于药物从鼻腔输送到大脑 [<xref ref-type="bibr" rid="hanspub.41663-ref23">23</xref>]。CS可以增强亲水性药物、核酸、蛋白质和肽渗鼻上皮细胞中的渗透性。作为载体材料而制备的CS纳米颗粒具有防止酶降解、控制药物释放和提高生物利用度的优点，同时毒性低和易制备，是一种极具潜力的药物传递载体。此外，壳聚糖纳米颗粒还具有控制活性剂释放的能力 [<xref ref-type="bibr" rid="hanspub.41663-ref24">24</xref>]，可溶于酸性水溶液，从而避免了在制备中使用一些有害的有机溶剂。</p><p>羧甲基壳聚糖纳米颗粒作为载体，经鼻腔给药时能够增加脑内的药物浓度 [<xref ref-type="bibr" rid="hanspub.41663-ref25">25</xref>]。以羧甲基壳聚糖纳米颗粒作为载体，经鼻给药(卡马西平)治疗癫痫，载药量和包封率均得到提高。有研究证明，卡马西平经羧甲基壳聚糖纳米颗粒装载后，通过猪鼻粘膜给药，会使药物生物利用度和脑内靶向性都得到增高 [<xref ref-type="bibr" rid="hanspub.41663-ref26">26</xref>]。沈淼山等人，制备了壳聚糖神经毒素纳米颗粒，对鼠经鼻腔给药后，发现它能显著增加血脑屏障的开放性，提高了脑内神经毒素的浓度，因此，作者认为壳聚糖纳米颗粒是携带大分子药物入脑的良好载体 [<xref ref-type="bibr" rid="hanspub.41663-ref27">27</xref>]。</p><p>壳聚糖纳米颗粒易溶于酸性溶液中，但在中性和碱性溶液中溶解度低，制备方法必须根据其要输送的药物而改变。除此之外，目前还没有经鼻腔给予壳聚糖纳米颗粒用于治疗人体脑部疾病的报道，其能否用于临床尚存在一些问题有待研究和证实。</p></sec></sec><sec id="s8"><title>4. 经鼻腔纳米颗粒给药治疗脑部疾病的局限性</title><p>经鼻腔给药是药物进入脑内的可行途径，作为载体的纳米颗粒必须是无毒的，且不会损害初级嗅觉神经元和嗅觉、不破坏鼻粘膜或破坏程度轻微；但一些纳米颗粒的材料以及制备中所使用的表面活性剂，可能存在一定毒性，因此制备适合鼻腔给药的纳米颗粒尚存在一定挑战，应减少一些可能确定毒性问题的表面活性剂的用量。关于表面活性剂毒性问题，有文献报道二氧化硅颗粒可以降低表面活性剂溶液的毒性，并且已经确定二氧化硅颗粒可以被认为是无毒的；尽管如此，活性剂毒性降低也要取决于表面活性剂的离子特性 [<xref ref-type="bibr" rid="hanspub.41663-ref28">28</xref>]。一般而言，多数纳米制剂是安全的，因为据目前所知，文献中还未有明确报道其致突变的作用，并且仅使用一些相对安全的药物制剂进行制备 [<xref ref-type="bibr" rid="hanspub.41663-ref6">6</xref>]。此外，纳米颗粒与鼻粘膜长期接触后，可能会导致鼻粘膜刺激、组织损伤、上皮/亚上皮毒性或纤毛毒性，还可能影响鼻腔内的微生物环境 [<xref ref-type="bibr" rid="hanspub.41663-ref29">29</xref>]。在设计合适的鼻-脑给药配方时，尽量考虑低剂量有效、有良好的水溶性或者必须能够使用增溶剂进行配制的药物，除此之外减少药物与鼻黏膜的接触时间 [<xref ref-type="bibr" rid="hanspub.41663-ref30">30</xref>]。纳米颗粒的物理特质对其穿过血脑屏障进入中枢神经系统有显著影响，所以选择时应综合考虑载体的尺寸、表面积、表面电荷、生物降解性、无毒、生物相容性、成本效益和靶向性等问题 [<xref ref-type="bibr" rid="hanspub.41663-ref31">31</xref>]。</p></sec><sec id="s9"><title>5. 结论和展望</title><p>鼻腔给药是很有前途的脑部给药方式，结合纳米颗粒载体的优势可以更好将药物靶向性地运送至脑内，提高进入中枢神经系统的药物浓度，这将可能是一种极具潜质的脑部疾病治疗方式。虽然目前多数研究尚停留在动物实验阶段，但一旦成功运用于人体，经鼻腔给药的纳米颗粒将有可能解决目前脑部疾病药物治疗中的许多棘手问题。</p></sec><sec id="s10"><title>基金项目</title><p>云南省卫生健康委员会–医学学科带头人项目资助(D-2018009)；云南省科技厅–昆明医科大学联合专项资助(202001AY070001-072)；云南省教育厅科学研究基金项目(2021Y342)；国家自然科学基金(82060313)。</p></sec><sec id="s11"><title>文章引用</title><p>邓爱林,柯腾飞,罗玥媛,廖承德. 经鼻腔给药的纳米颗粒及其治疗脑部疾病的进展Nanoparticles Administered through Nasal Cavity and Its Progress in the Treatment of Brain Diseases[J]. 生物医学, 2021, 11(02): 69-74. https://doi.org/10.12677/HJBM.2021.112010</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41663-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Mistry, A., Stolnik, S. and Illum, L. (2009) Nanoparticles for Direct Nose-to-Brain Delivery of Drugs. International Journal of Pharmaceutics, 379, 146-157. https://doi.org/10.1016/j.ijpharm.2009.06.019</mixed-citation></ref><ref id="hanspub.41663-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J.K. and Ali, J. (2014) Insights into Direct Nose to Brain Delivery: Current Status and Future Perspective. Drug Delivery, 21, 75-86. https://doi.org/10.3109/10717544.2013.838713</mixed-citation></ref><ref id="hanspub.41663-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Djupesland, P.G., Messina, J.C. and Mahmoud, R.A. (2014) The Nasal Approach to Delivering Treatment for Brain Diseases: An Anatomic, Physiologic, and Delivery Technology Overview. Therapeutic Delivery, 5, 709-733.  
https://doi.org/10.4155/tde.14.41</mixed-citation></ref><ref id="hanspub.41663-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ying, W. (2008) The Nose May Help the Brain: Intranasal Drug Delivery for Treating Neurological Diseases. Future Neurology, 3, 1-4. &lt;br&gt;https://doi.org/10.2217/14796708.3.1.1</mixed-citation></ref><ref id="hanspub.41663-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Dhuria, S.V., Hanson, L.R. and Frey, W.H. (2010) Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations. Journal of Pharmaceutical Sciences, 99, 1654-1673.  
&lt;br&gt;https://doi.org/10.1002/jps.21924</mixed-citation></ref><ref id="hanspub.41663-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bonferoni, M.C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., et al. (2019) Nanoemulsions for “Nose-to-Brain” Drug Delivery. Pharmaceutics, 11, 84. &lt;br&gt;https://doi.org/10.3390/pharmaceutics11020084</mixed-citation></ref><ref id="hanspub.41663-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Fan, Y., Chen, M., Zhang, J., Maincent, P., Xia, X. and Wu, W. (2018) Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases. Critical Reviews in Therapeutic Drug Carrier Systems, 35, 433-467. &lt;br&gt;https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018024697</mixed-citation></ref><ref id="hanspub.41663-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Silva, G.A. (2005) Nanotechnology Approaches for the Regeneration and Neuroprotection of the Central Nervous System. Surgical Neurology, 63, 301-306. &lt;br&gt;https://doi.org/10.1016/j.surneu.2004.06.008</mixed-citation></ref><ref id="hanspub.41663-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Schneider, C.S., Xu, Q., Boylan, N.J., Chisholm, J., Tang, B.C., Schuster, B.S., et al. (2017) Nanoparticles That Do Not Adhere to Mucus Provide Uniform and Long-Lasting Drug Delivery to Airways Following Inhalation. Science Advances, 3, e1601556. &lt;br&gt;https://doi.org/10.1126/sciadv.1601556</mixed-citation></ref><ref id="hanspub.41663-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Battaglia, L. and Gallarate, M. (2012) Lipid Nanoparticles: State of the Art, New Preparation Methods and Challenges in Drug Delivery. Expert Opinion on Drug Delivery, 9, 497-508. &lt;br&gt;https://doi.org/10.1517/17425247.2012.673278</mixed-citation></ref><ref id="hanspub.41663-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Naqvi, S., Panghal, A. and Flora, S.J.S. (2020) Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs. Frontiers in Neuroscience, 14, 494. &lt;br&gt;https://doi.org/10.3389/fnins.2020.00494</mixed-citation></ref><ref id="hanspub.41663-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Shah, B., Khunt, D., Bhatt, H., Misra, M. and Padh, H. (2015) Application of Quality by Design Approach for Intranasal Delivery of Rivastigmine Loaded Solid Lipid Nanoparticles: Effect on Formulation and Characterization Parameters. European Journal of Pharmaceutical Sciences, 78, 54-66. &lt;br&gt;https://doi.org/10.1016/j.ejps.2015.07.002</mixed-citation></ref><ref id="hanspub.41663-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Muntimadugu, E., Dhommati, R., Jain, A., Challa, V.G., Shaheen, M. and Khan, W. (2016) Intranasal Delivery of Nanoparticle Encapsulated Tarenflurbil: A Potential Brain Targeting Strategy for Alzheimer’s Disease. European Journal of Pharmaceutical Sciences, 92, 224-234. &lt;br&gt;https://doi.org/10.1016/j.ejps.2016.05.012</mixed-citation></ref><ref id="hanspub.41663-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bhatt, R., Singh, D., Prakash, A. and Mishra, N. (2015) Development, Characterization and Nasal Delivery of Rosmarinic Acid-Loaded Solid Lipid Nanoparticles for the Effective Management of Huntington’s Disease. Drug Delivery, 22, 931-939. &lt;br&gt;https://doi.org/10.3109/10717544.2014.880860</mixed-citation></ref><ref id="hanspub.41663-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Patel, S., Chavhan, S., Soni, H., Babbar, A.K., Mathur, R., Mishra, A.K., et al. (2011) Brain Targeting of Risperidone-Loaded Solid Lipid Nanoparticles by Intranasal Route. Journal of Drug Targeting, 19, 468-474.  
&lt;br&gt;https://doi.org/10.3109/1061186X.2010.523787</mixed-citation></ref><ref id="hanspub.41663-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Das, S., Ng, W.K. and Tan, R.B. (2012) Are Nanostructured Lipid Carriers (NLCs) Better than Solid Lipid Nanoparticles (SLNs): Development, Characterizations and Comparative Evaluations of Clotrimazole-Loaded SLNs and NLCs? European Journal of Pharmaceutical Sciences, 47, 139-151. &lt;br&gt;https://doi.org/10.1016/j.ejps.2012.05.010</mixed-citation></ref><ref id="hanspub.41663-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Comfort, C., Garrastazu, G., Pozzoli, M. and Sonvico, F. (2015) Opportunities and Challenges for the Nasal Administration of Nanoemulsions. Current Topics in Medicinal Chemistry, 15, 356-368.  
&lt;br&gt;https://doi.org/10.2174/1568026615666150108144655</mixed-citation></ref><ref id="hanspub.41663-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Sarker, D.K. (2005) Engineering of Nanoemulsions for Drug Delivery. Current Drug Delivery, 2, 297-310.  
&lt;br&gt;https://doi.org/10.2174/156720105774370267</mixed-citation></ref><ref id="hanspub.41663-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Patel, R.J. and Parikh, R.H. (2020) Intranasal Delivery of Topiramate Nanoemulsion: Pharmacodynamic, Pharmacokinetic and Brain Uptake Studies. International Journal of Pharmaceutics, 585, Article ID: 119486.  
&lt;br&gt;https://doi.org/10.1016/j.ijpharm.2020.119486</mixed-citation></ref><ref id="hanspub.41663-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kaur, A., Nigam, K., Bhatnagar, I., Sukhpal, H., Awasthy, S., Shankar, S., et al. (2020) Treatment of Alzheimer’s Diseases Using Donepezil Nanoemulsion: An Intranasal Approach. Drug Delivery and Translational Research, 10, 1862-1875. &lt;br&gt;https://doi.org/10.1007/s13346-020-00754-z</mixed-citation></ref><ref id="hanspub.41663-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Arora, A., Kumar, S., Ali, J. and Baboota, S. (2020) Intranasal Delivery of Tetrabenazine Nanoemulsion via Olfactory Region for Better Treatment of Hyperkinetic Movement Associated with Huntington’s Disease: Pharmacokinetic and Brain Delivery Study. Chemistry and Physics of Lipids, 230, Article ID: 104917.  
&lt;br&gt;https://doi.org/10.1016/j.chemphyslip.2020.104917</mixed-citation></ref><ref id="hanspub.41663-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Singh, Y., Meher, J.G., Raval, K., Khan, F.A., Chaurasia, M., Jain, N.K., et al. (2017) Nanoemulsion: Concepts, Development and Applications in Drug Delivery. Journal of Controlled Release, 252, 28-49.  
&lt;br&gt;https://doi.org/10.1016/j.jconrel.2017.03.008</mixed-citation></ref><ref id="hanspub.41663-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Yu, S., Xu, X., Feng, J., Liu, M. and Hu, K. (2019) Chitosan and Chitosan Coating Nanoparticles for the Treatment of Brain Disease. International Journal of Pharmaceutics, 560, 282-293. &lt;br&gt;https://doi.org/10.1016/j.ijpharm.2019.02.012</mixed-citation></ref><ref id="hanspub.41663-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Garg, U., Chauhan, S., Nagaich, U. and Jain, N. (2019) Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting. Advanced Pharmaceutical Bulletin, 9, 195-204. &lt;br&gt;https://doi.org/10.15171/apb.2019.023</mixed-citation></ref><ref id="hanspub.41663-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Illum, L. (2003) Nasal Drug Delivery—Possibilities, Problems and Solutions. Journal of Controlled Release, 87, 187-198. &lt;br&gt;https://doi.org/10.1016/S0168-3659(02)00363-2</mixed-citation></ref><ref id="hanspub.41663-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Liu, S., Yang, S. and Ho, P.C. (2018) Intranasal Administration of Carbamazepine-Loaded Carboxymethyl Chitosan Nanoparticles for Drug Delivery to the Brain. Asian Journal of Pharmaceutical Sciences, 13, 72-81.  
&lt;br&gt;https://doi.org/10.1016/j.ajps.2017.09.001</mixed-citation></ref><ref id="hanspub.41663-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">沈淼山, 张苏宏, 邱璐琦, 阮叶萍. 壳聚糖神经毒素纳米粒鼻腔给药对血脑屏障开放性的影响[J]. 中草药, 2017, 48(12): 2461-2465.</mixed-citation></ref><ref id="hanspub.41663-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ríos, F., Fernández-Arteaga, A., Fernández-Serrano, M., Jurado, E. and Lechuga, M. (2018) Silica Micro- and Nanoparticles Reduce the Toxicity of Surfactant Solutions. Journal of Hazardous Materials, 353, 436-443.  
&lt;br&gt;https://doi.org/10.1016/j.jhazmat.2018.04.040</mixed-citation></ref><ref id="hanspub.41663-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Haffejee, N., Du Plessis, J., Müller, D.G., Schultz, C., Kotzé, A.F. and Goosen, C. (2001) Intranasal Toxicity of Selected Absorption Enhancers. Die Pharmazie, 56, 882-888.</mixed-citation></ref><ref id="hanspub.41663-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Musumeci, T., Bonaccorso, A. and Puglisi, G. (2019) Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview. Pharmaceutics, 11, 118. &lt;br&gt;https://doi.org/10.3390/pharmaceutics11030118</mixed-citation></ref><ref id="hanspub.41663-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Chakraborty, S., Dhakshinamurthy, G.S. and Misra, S.K. (2017) Tailoring of Physicochemical Properties of Nanocarriers for Effective Anti-Cancer Applications. Journal of Biomedical Materials Research Part A, 105, 2906-2928.  
&lt;br&gt;https://doi.org/10.1002/jbm.a.36141</mixed-citation></ref></ref-list></back></article>